| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.22 | 1e-10 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.17 | 1e-06 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | 0.17 | 6e-06 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.17 | 7e-06 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.23 | 1e-05 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.24 | 2e-05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.21 | 4e-05 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | -0.14 | 4e-05 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.19 | 6e-05 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.15 | 7e-05 |